Light therapy for a type of early macular degeneration
Part of Eyes & vision clinical trials.
This study tests whether a special low-level laser treatment (photobiomodulation) can help people with an early form of age-related macular degeneration called reticular pseudodrusen. It may slow vision loss or protect your eyes from getting worse.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 50 years or older
- You have a diagnosis of reticular pseudodrusen (a type of drusen) related to age-related macular degeneration
- Your vision (with glasses) is between 20/20 and 20/400
- You have not had any prior treatment for age-related macular degeneration (except vitamin supplements)
- You do not have more advanced forms of the disease, such as geographic atrophy or abnormal blood vessels
- You have not had certain eye surgeries (like vitrectomy or corneal transplant) in the study eye
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether low-level red-light therapy can help people with dry age-related macular degeneration (AMD), a common cause of vision loss in older adults. The therapy is a painless light treatment that you might receive in multiple sessions, and the study aims to see if it can slow or improve vision decline.
This trial tests a new stem-cell treatment for people with advanced dry age-related macular degeneration (AMD), a condition that causes blurring or loss of central vision. It aims to replace damaged cells in the back of the eye to potentially slow vision loss and improve day-to-day sight.
This trial studies a mild (“subthreshold”) laser treatment for reticular pseudodrusen (RPD) caused by age-related macular degeneration (AMD). If you qualify, the goal is to see whether the laser helps preserve or improve vision by targeting these specific eye changes.
This trial tests a new light-based treatment for intermediate age-related macular degeneration (AMD), a common eye condition that can lead to vision loss. The goal is to see if it is safe and helps slow down the disease.
This study tests a light-based therapy called photobiomodulation for dry age-related macular degeneration (AMD). It aims to see if this treatment can help preserve vision in the dry AMD eye, and includes people who have dry AMD in one eye and wet AMD in the other.
This study tests a new laser treatment (MacuTherm) for intermediate age-related macular degeneration (iAMD), an eye condition that affects central vision. The study aims to see if this treatment can slow or prevent progression to more advanced stages of the disease.
Hear when a new AMD - Age-Related Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.